Jubilant Pharmova Limited — Updates, 22-05-2026: Press Release

Jubilant Pharmova achieved robust revenue growth of 14% to 8,280 Cr, with EBITDA up 8% to 1,326 Cr. CDMO Sterile Injectables saw strong performance, onboarding a large oncology product. Radiopharma's Ruby-Fill® grew, but segment EBITDA faced temporary production issues at a facility undergoing remediation. Generics profitability improved significantly.